Traws Pharma, Inc. (TRAW:NASDAQ) closed at $0.369 on October 16, 2026, down 9.04% on the day. The stock trades 88.6% below its 52-week high of $3.23 and 0.3% above its 52-week low of $0.368. Over the past year, it lost 87.1%. Traws Pharma, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -11.23% | -31.61% | -39.46% | -73.43% | -87.09% |
In 252 trading sessions since October 16, 2025, TRAW closed higher on 104 days (41%). Its best day was May 8, 2026 (+28.24%) and its worst was June 15, 2026 (-40.63%). The stock moved 10% or more in a single session 35 times. It opened at least 5% above the previous day's high 2 times.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Find more stocks like TRAW with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.